as Executive Vice President in Charge of Research & Development
Strasbourg, France, September 23, 2014 - Transgene (NYSE-Euronext: TNG) today announced the appointment of Eric Quéméneur, PhD as Executive Vice President in charge of Research and Development. In this position, he will lead all of the Company's research activities, from discovery through pre-clinical. Dr. Quéméneur is a member of Transgene's Management Committee.
Philippe Archinard, Chairman and Chief Executive Officer, said "I am very pleased to welcome Eric Quéméneur to Transgene. He has extensive experience effectively leading life sciences research teams and managing research collaborations. He is a wonderful addition to the Transgene senior management team and will be a great asset for the Company's development."
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||2.58 (c)||-0.39%||29 253|